Quality of life and cost‐effectiveness of intravesical gemcitabine/docetaxel vs <scp>BCG</scp> in <scp>BCG</scp> ‐naïve non‐muscle‐invasive bladder cancer
Sequential Gem/Doce delivered optimal short-term survival outcomes, favourable patient-reported QoL and safety profile, and attractive cost per avoided recurrence/progression compared with BCG, supporting its adoption as a clinically and economically viable alternative in resource-constrained NMIBC care.
Authors
- Sameer Trivedi
- Ujwal Kumar
- Anil Kumar (ORCID: https://orcid.org/0000-0002-1691-0098)
- A S Srivastava
- Yashasvi Singh (ORCID: https://orcid.org/0009-0005-9531-6386)
- S.N. Sankhwar
- Sahil Data
- Lalit Kumar
Institutions
- Banaras Hindu University (IN)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1111/bju.70126
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00